Abstract
ObjectiveThe objective of this study was to prospectively evaluate the clinical features of chemotherapy‐induced oral mucositis (CIOM) in adult patients with acute leukemia and the aggravating factors for such symptoms.SubjectsThirty‐seven prospective patients aged ≥19 years with acute leukemia undergoing chemotherapy were enrolled. Oral and clinical investigations were performed at baseline and on Day 14 after starting chemotherapy. The presence and severity of cancer‐induced oral mucositis were demonstrated using the World Health Organization (WHO) scoring system.ResultsOn Day 14, we found that oral mucositis had developed in eight patients (21.6%). Hematopoietic stem cell transplantation (HSCT) in patients was a predictor of increased WHO scores (β = 1.937, p < .001). Regarding oral sites, ventral tongue (β = 1.670), soft palate (β = 1.242), and buccal mucosa (β = 0.593) were predictors for increased scores. In addition, the increase in WHO scores was positively correlated with the number of oral lesions (r = .521), the difficulty in eating (r = .250), and the overall oral health (r = .534; all p < .05).ConclusionThe main factors affecting the severity of CIOM symptoms were the treatment with HSCT and the location of oral lesions. The incidence of CIOM and WHO scores were not significantly different between the subgroups of disease. Our findings will help clinicians investigate the oral findings after chemotherapy in adult patients with acute leukemia.
Highlights
Leukemia is a kind of hematological cancer that is caused by an overproduction of white blood cell (WBC)-forming tissues resulting in a marked increase in circulating immature or abnormal WBCs (Shysh et al, 2017)
A significant percentage of oral lesions that are caused by anticancer treatments may be reversible, whereas little is known about how hematopoietic stem cell transplantation (HSCT) affects chemotherapy-induced oral mucositis (CIOM) in patients with acute leukemia
We evaluated whether clinical factors such as location of the oral lesion, the number of lesions, subtype of acute leukemia, and treatment with HSCT affect the development and severity of CIOM in patients with acute leukemia
Summary
Leukemia is a kind of hematological cancer that is caused by an overproduction of white blood cell (WBC)-forming tissues resulting in a marked increase in circulating immature or abnormal WBCs (Shysh et al, 2017). A significant percentage of oral lesions that are caused by anticancer treatments may be reversible, whereas little is known about how HSCT affects CIOM in patients with acute leukemia. The aim of the current study was to prospectively determine the clinical features of CIOM in adult patients with acute leukemia and to compare their oral signs and symptoms between the two subgroups, ALL and AML. We evaluated whether clinical factors such as location of the oral lesion, the number of lesions, subtype of acute leukemia, and treatment with HSCT affect the development and severity of CIOM in patients with acute leukemia.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
